This company has been marked as potentially delisted and may not be actively trading. Edge Therapeutics (EDGE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock EDGE vs. AKRO, RNA, RYTM, PBH, PTCT, ZLAB, MRUS, SRPT, CYTK, and ACADShould you be buying Edge Therapeutics stock or one of its competitors? The main competitors of Edge Therapeutics include Akero Therapeutics (AKRO), Avidity Biosciences (RNA), Rhythm Pharmaceuticals (RYTM), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Merus (MRUS), Sarepta Therapeutics (SRPT), Cytokinetics (CYTK), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "medical" sector. Edge Therapeutics vs. Its Competitors Akero Therapeutics Avidity Biosciences Rhythm Pharmaceuticals Prestige Consumer Healthcare PTC Therapeutics Zai Lab Merus Sarepta Therapeutics Cytokinetics ACADIA Pharmaceuticals Edge Therapeutics (NASDAQ:EDGE) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment. Do insiders & institutionals have more ownership in EDGE or AKRO? 28.0% of Edge Therapeutics shares are owned by institutional investors. 37.1% of Edge Therapeutics shares are owned by insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate EDGE or AKRO? Akero Therapeutics has a consensus price target of $82.50, indicating a potential upside of 48.33%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akero Therapeutics is more favorable than Edge Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edge Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor EDGE or AKRO? In the previous week, Akero Therapeutics had 25 more articles in the media than Edge Therapeutics. MarketBeat recorded 25 mentions for Akero Therapeutics and 0 mentions for Edge Therapeutics. Akero Therapeutics' average media sentiment score of 0.43 beat Edge Therapeutics' score of 0.00 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Edge Therapeutics Neutral Akero Therapeutics Neutral Does the MarketBeat Community prefer EDGE or AKRO? Edge Therapeutics received 58 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 66.79% of users gave Edge Therapeutics an outperform vote while only 65.75% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformEdge TherapeuticsOutperform Votes17766.79% Underperform Votes8833.21% Akero TherapeuticsOutperform Votes11965.75% Underperform Votes6234.25% Which has more volatility and risk, EDGE or AKRO? Edge Therapeutics has a beta of 3.65, suggesting that its stock price is 265% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Which has higher earnings and valuation, EDGE or AKRO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdge TherapeuticsN/AN/A-$40.86MN/AN/AAkero TherapeuticsN/AN/A-$151.76M-$1.95-28.52 Is EDGE or AKRO more profitable? Akero Therapeutics' return on equity of -32.46% beat Edge Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edge TherapeuticsN/A -81.29% -56.92% Akero Therapeutics N/A -32.46%-29.83% SummaryAkero Therapeutics beats Edge Therapeutics on 7 of the 13 factors compared between the two stocks. Get Edge Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDGE vs. The Competition Export to ExcelMetricEdge TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22B$6.88B$5.58B$8.50BDividend YieldN/A2.53%5.28%4.17%P/E RatioN/A8.5527.1919.64Price / SalesN/A262.61408.78152.17Price / CashN/A65.8538.3234.64Price / Book40.886.536.974.60Net Income-$40.86M$143.48M$3.23B$248.06M Edge Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDGEEdge TherapeuticsN/A$38.83+0.2%N/A+1,304.5%$1.22BN/A0.00N/AAKROAkero Therapeutics3.7129 of 5 stars$53.94+1.8%$82.50+52.9%+120.5%$4.30BN/A-14.3830Trending NewsInsider TradeRNAAvidity Biosciences2.1144 of 5 stars$35.59+4.0%$66.38+86.5%-16.2%$4.29B$8.93M-12.36190Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionRYTMRhythm Pharmaceuticals4.1551 of 5 stars$66.18+2.8%$76.62+15.8%+49.1%$4.21B$136.86M-15.28140Positive NewsInsider TradePBHPrestige Consumer Healthcare4.1387 of 5 stars$84.61-0.2%$93.33+10.3%+28.5%$4.18B$1.14B19.81540Positive NewsPTCTPTC Therapeutics3.8562 of 5 stars$51.73+1.2%$63.75+23.2%+35.3%$4.10B$1.77B-8.711,410Analyst RevisionGap DownZLABZai Lab1.4239 of 5 stars$36.54+1.3%$47.37+29.6%+115.2%$4.03B$418.33M-13.191,950Positive NewsAnalyst RevisionMRUSMerus3.0725 of 5 stars$56.01-2.7%$85.83+53.2%-2.2%$3.88B$54.73M-14.1837High Trading VolumeSRPTSarepta Therapeutics4.7609 of 5 stars$39.21-0.8%$122.61+212.7%-68.9%$3.85B$2.23B31.37840CYTKCytokinetics4.3629 of 5 stars$32.08-1.0%$72.31+125.4%-38.6%$3.83B$19.22M-5.96250Analyst RevisionACADACADIA Pharmaceuticals3.2501 of 5 stars$21.34-2.0%$26.54+24.4%+41.4%$3.57B$996.28M27.36510Analyst Revision Related Companies and Tools Related Companies Akero Therapeutics Competitors Avidity Biosciences Competitors Rhythm Pharmaceuticals Competitors Prestige Consumer Healthcare Competitors PTC Therapeutics Competitors Zai Lab Competitors Merus Competitors Sarepta Therapeutics Competitors Cytokinetics Competitors ACADIA Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDGE) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EDGE Stock Free EDGE Stock Alerts